While NO signaling in PAH patients is aberrant, sGC is expressed in PASMCs of PAH patients (Schermuly et al., 2008), making sGC stimulators attractive agents for increasing cGMP levels in these patients. This evidence concerns the gene SGCB and pulmonary arterial hypertension.